Biostem Technologies (NASDAQ:BSEM) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Biostem Technologies (NASDAQ:BSEM) to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings initiated coverage on Biostem Technologies in a research report on Wednesday, August 19th. They set a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Biostem Technologies currently has an average rating of “Sell”.

Biostem Technologies Trading Up 2.8%

NASDAQ BSEM opened at $3.71 on Friday. Biostem Technologies has a 1-year low of $2.25 and a 1-year high of $8.40. The company has a 50 day moving average of $3.57 and a 200-day moving average of $4.47. The firm has a market cap of $66.22 million, a price-to-earnings ratio of -2.31 and a beta of 0.12.

Biostem Technologies Company Profile

BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.

Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.